International Journal of Hematology

DOI: 10.1007/s12185-019-02686-y Pages: 364-369

Long-term outcome and chimerism in patients with Wiskott–Aldrich syndrome treated by hematopoietic cell transplantation: a retrospective nationwide survey

1. Hokkaido University Hospital, Department of Pediatrics

2. Tokai University School of Medicine, Department of Cell Transplantation and Regenerative Medicine

3. Children’s Medical Center, Japanese Red Cross Nagoya First Hospital, Department of Hematology and Oncology

4. Osaka City General Hospital, Department of Pediatric Hematology/Oncology

5. Saitama Children’s Medical Center, Department of Hematology/Oncology

6. The University of Tokyo Hospital, Department of Cell Therapy and Transplantation Medicine (Pediatrics)

7. Nara Medical University Hospital, Department of Pediatrics

8. Osaka Medical Center and Research Institute for Maternal and Child Health, Department of Hematology/Oncology

9. Medical Hospital, Tokyo Medical and Dental University, Department of Pediatrics

10. National Kyushu Cancer Center, Department of Pediatrics

11. Osaka University Graduate School of Medicine, Department of Pediatrics

12. Jichi Medical University, Children’s Medical Center Tochigi

13. Japanese Data Center for Hematopoietic Cell Transplantation

14. Nagoya University Graduate School of Medicine, Department of Healthcare Administration

Correspondence to:
Akihiro Iguchi
Tel: 81-11-706-5954



We analyzed the outcomes of allogeneic stem cell transplantation (SCT) and risk factors for chimerism in 108 patients with Wiskott–Aldrich syndrome (WAS) who were registered with The Japan Society for Hematopoietic Cell Transplantation between January 1985 and December 2016. A preparative conditioning regimen consisting of myeloablative conditioning (MAC) was provided to 76 patients, and reduced-intensity conditioning was provided to 30 patients. Fifty-one patients received prophylaxis against graft-versus-host disease (GVHD) with cyclosporine, and 51 patients received tacrolimus (Tac). Chimerism analyses had been performed in 91 patients. Neutrophil engraftment was achieved in 91 patients (84.3%). The engraftment rate was significantly higher in patients who received Tac for GVHD prophylaxis (p = 0.028). Overall survival rate (OS) was significantly higher in patients with complete chimerism than in patients with mixed chimerism (88.2 ± 6.1% and 66.7 ± 9.9%, respectively, p = 0.003). Multivariate analysis showed that the rate of complete chimerism in patients who received MAC including cyclophosphamide (CY) at a dose of 200 mg/kg was significantly higher (p = 0.021) than that in patients who received other conditioning. Thus, MAC including CY at a dose of 200 mg/kg and Tac for GVHD prophylaxis were optimal conditions of SCT for patients with WAS under existing study.

To access the full text, please Sign in

If you have institutional access, please click here

Share the Knowledge